Background. Red blood cell-derived microparticles are biologically active, submicron vesicles shed by erythrocytes during storage. Recent clinical studies have linked the duration of red blood cell storage with thromboembolic events in critically ill transfusion recipients. In the present study, we hypothesized that microparticles from aged packed red blood cell units promote a hypercoagulable state in a murine model of transfusion. Methods. Microparticles were isolated from aged, murine packed red blood cell units via serial centrifugation. Healthy male C57BL/6 mice were transfused with microparticles or an equivalent volume of vehicle, and whole blood was harvested for analysis via rotational thromboelastometry. Serum was harvested from a separate set of mice after microparticles or saline injection, and analyzed for fibrinogen levels. Red blood cell-derived microparticles were analyzed for their ability to convert prothrombin to thrombin. Finally, mice were transfused with either red blood cell microparticles or saline vehicle, and a tail bleeding time assay was performed after an equilibration period of 2, 6, 12, or 24 hours. Results. Mice injected with red blood cell-derived microparticles demonstrated an accelerated clot formation time (109.3 ± 26.9 vs 141.6 ± 28.2 sec) and increased α angle (68.8 ± 5.0 degrees vs 62.8 ± 4.7 degrees) compared with control (each P < .05). Clotting time and maximum clot firmness were not significantly different between the 2 groups. Red blood cell-derived microparticles exhibited a hundredfold greater conversion of prothrombin substrate to its active thrombin form (66.60 ± 0.03 vs 0.70 ± 0.01 peak OD; P < .0001). Additionally, serum fibrinogen levels were lower in microparticles-injected mice compared with saline vehicle, suggesting thrombin-mediated conversion to insoluble fibrin (14.0 vs 16.5 μg/mL, P < .05). In the tail bleeding time model, there was a more rapid cessation of bleeding at 2 hours posttransfusion (90.6 vs 123.7 sec) and 6 hours posttransfusion (87.1 vs 141.4 sec) in microparticlesinjected mice as compared with saline vehicle (each P < .05). There was no difference in tail bleeding time at 12 or 24 hours. Conclusion. Red blood cell-derived microparticles induce a transient hypercoagulable state through accelerated activation of clotting factors.
Hemorrhagic shock accounts for a third of these deaths, [3] [4] [5] with the majority of these deaths being potentially preventable. 6, 7 While resuscitative strategies are an area of ongoing research, 8, 9 blood transfusion has remained the standard of care throughout the modern medical era. 10 Current Food & Drug Administration (FDA) regulations allow the storage of packed red blood cells (pRBC) for up to 42 days. 11 Throughout the storage period, erythrocytes demonstrate a progressive series of biochemical and morphologic changes collectively termed the RBC "storage lesion." 12 Microparticles (MPs) are submicron vesicles released from aging RBCs as a key element in the storage lesion. [12] [13] [14] Previously dismissed as nonfunctional cellular debris, MPs have recently been shown to play integral roles in intracellular signaling and various disease states. [15] [16] [17] While the exact functions of RBCderived MPs are an area of ongoing study, their biochemical composition has been well-characterized. Specifically, these spherical, subcellular fragments contain residual hemoglobin and RBC Supported by grants R01 GM107625 and T32 GM008478-23 from the National Institutes of Health.
Portions of this work have been presented at the 39th Annual Conference on Shock in Hilton Austin, Austin, TX, June 11-14, 2016 , and at the 12th Annual Academic Surgical Congress in Las Vegas, NV, February 7-9, 2017. proteins encompassed by a phosphatidylserine-rich phospholipid membrane. 18 Given the possible role of phosphatidylserine in regulating coagulation, 19 preliminary studies have investigated the effect of RBCderived MPs on individual coagulation factors. Both procoagulant (e.g., thrombin generation) and anticoagulant properties (e.g., activated protein C regulation) of RBC-derived MPs have been observed in an in vitro setting. 20 The aggregate effect of MPs on recipient coagulation parameters, however, remains poorly understood. In the present study, we hypothesized that RBC-derived MPs promote an overall hypercoagulable state in the transfusion recipient.
Materials and Methods
Animal model C57BL/6 mice aged 8-10 weeks were obtained from Jackson Laboratories (Bar Harbor, ME) and used for all experiments. They were fed water and a standard laboratory diet ad libitum, and acclimated for 2 weeks in a climate-controlled environment with a daily light-dark cycle. All mice weighed 21 to 30 g prior to experimentation. All experiments were approved by the Institutional Animal Care and Use Committee at the University of Cincinnati.
Murine blood harvesting protocol
Packed RBC units were prepared using a modification of a previously described technique. 21 Briefly, donor mice were anesthetized with intraperitoneal pentobarbital at 0.1 mg/g body weight, and then whole blood was harvested via open cardiac puncture. Fresh whole blood was immediately mixed with citrate phosphate double dextrose anticoagulant in a 1:7 ratio to prevent inadvertent clotting. Anticoagulated whole blood was centrifuged, after which plateletrich plasma and leukocyte-rich buffy coat were removed. The remnant erythrocyte pellet was washed twice with a 10:1 ratio of phosphate-buffered saline (PBS) in order to purify the RBC unit of any platelet contamination. The RBC pellet was then resuspended in additive solution-3 storage solution in a 2:9 ratio.
Packed RBC units were stored for 14 days at 4°C in lightprotected conditions. Previous studies have demonstrated that murine erythrocytes accumulate age-related changes at an accelerated rate compared with human pRBCs. 21 Current FDA regulations allow human pRBC units to be stored up to 42 days under similar conditions. Therefore, the 14-day storage duration was chosen as it reflects the murine equivalent of 42-day storage in human pRBC units. After the storage period, serial centrifugation was used to remove any cellular components in the pRBC unit, and RBCderived MPs were isolated via ultracentrifugation as previously described. 13 
Microparticle characterization
MPs isolated from one mL of mouse pRBCs were labelled with conjugated fluorescent antibodies (Affymetrix, Santa Clara, CA) for Ter119 (murine erythrocyte marker), CD41 (murine platelet marker), and CD45 (murine leukocyte marker). The final MP concentration was determined via dual-laser flow cytometry, which was gated for events ranging from 0.1 to 1.0 μm. Using separate gates for each fluorophore, the quantity of Ter119-positive events was compared with CD41-positive and CD45-positive events.
Thromboelastometry
Rotational thromboelastometry (ROTEM; TEM Systems Inc, Durham, NC) analysis was performed to assess and quantify changes in coagulation parameters in accordance with manufacturer instructions. For ex vivo experiments, fresh whole blood was harvested from healthy male C57BL/6 as described previously, then anticoagulated with sterile 0.1 M citrate solution. Citrated blood was treated with RBC-derived MPs or saline vehicle in a 1:5 ratio, and then analyzed within 1 min of whole blood collection. Nonactivated TEM (NATEM) analysis was used to determine overall coagulation; extrinsic pathway TEM (EXTEM) was used to determine coagulation via the extrinsic pathway; and fibrin TEM (FIBTEM) was used to quantify the fibrin contribution to clot. EXTEM and FIBTEM were performed via addition of 20 μL of thromboplastin or cytochalasin D, respectively, to 300 μL of citrated blood prior to thromboelastometric analysis per manufacturer protocol. Maximum clot firmness (MCF), α angle, clotting time (CT), and clot formation time (CFT) were determined for each sample. In vivo experiments were performed in a similar fashion, with fresh whole blood harvested from mice injected with RBC-derived MPs or saline vehicle.
On ROTEM, the x-axis represents time and y-axis measures clot formation and strength of the thrombus. 22 CT reflects the activation and propagation of the clotting cascade. CFT and α angle, which are derived from the same variables, reflect the cleavage and activation of fibrinogen. MCF measures the contribution of both fibrin and platelets to the strength of the thrombus, and is defined as the maximal y-axis amplitude.
Thrombus characterization
Percent contribution of platelets (%MCFPLT) to the overall clot was calculated with the following equation: (EXTEMMCF -FIBTEMMCF)/ EXTEMMCF, as previously described by Midura et al. 23 Fibrinogen contribution to thrombus was quantified via FIBTEMMCF, using cytochalasin D to impair platelet activation prior to thromboelastometry.
Clotting factor analysis
Healthy male C57BL/6 mice were intravenously transfused with RBC-derived MPs or an equivalent volume (200 μl) of saline vehicle. This volume is approximately that which a 70 kg human would receive with a transfusion of 2 units of pRBCs. At intervals, whole blood was collected via open cardiac puncture, anticoagulated, and then centrifuged to isolate the plasma fraction. Fibrinogen concentration of plasma samples was measured via ELISA kit (MyBioSource, San Diego, CA) according to the manufacturer's instructions. In separate experiments, whole blood was separated into cellular and serum fractions using serum separator tubes, then serum was analyzed for D-dimer and fibrinogen degradation product levels via ELISA kits (MyBioSource, San Diego, CA) according to the manufacturer's instructions.
Thrombin activation was determined using Zymuphen MPActivity functional assay (Aniara Diagnostica, West Chester, OH). Briefly, RBC-derived MPs were diluted 1:20 and added to microplate wells supplemented with Factor Xa-Va mixture, calcium, thrombin inhibitors, and purified prothrombin. The activity of the generated thrombin substrate was measured via spectrophotometry. An equivalent volume of saline vehicle served as negative control. The assay was performed per manufacturer protocol.
Tail bleeding time assay
Healthy male C57BL/6 mice aged 8 to 10 weeks were anesthetized under 2% inhaled isofluorane. MPs isolated from 1 mL of murine pRBC were resuspended in 200 μL of PBS and intravenously transfused via penile vein. An equivalent volume of PBS vehicle served as a control. A tail bleeding time (TBT) assay was then performed at 2, 6, 12, and 24 hours after treatment. 24, 25 Mice were anesthetized with intraperitoneal pentobarbital at 0.1 mg/g body weight, and then placed on a heating pad to preclude hypothermia as a confounding factor. Mouse tails were cleansed with 140-proof ethanol. A 10-blade Bard-Parker surgical scalpel was used to resect exactly 5 mm of mouse tail measured from the tip (Aspen Surgical, Caledonia, MI). 25 New scalpel blades were used for each experiment to prevent inadvertent crush injury to the tail vein. The freshly cut tail was immediately immersed in normal saline (NS) warmed to 37°C. TBT was measured from time of incision to time of cessation of bleeding. After cessation of bleeding, tails were observed for an additional 60 seconds to ensure that rebleeding did not occur.
Statistical analysis
Mouse experiments were conducted in triplicate to ensure repeatability of findings. Results are reported in means and standard deviation where applicable. Two-tailed Student t tests were used to compare treatment groups. Analysis of variance (ANOVA) tests were used to compare differences between ≥3 groups.
Results
In initial experiments, we characterized the MPs isolated from stored pRBC units. Utilizing flow cytometry, we determined that MPs derived from murine pRBC units stored for 14 days yielded a concentration of 10.7 ± 1.1 x 10 6 MPs/mL of murine pRBCs, consistent with our previous data. 13 Flow cytometry using antibodies to Ter119 (RBC-specific antigen), and CD41 (platelet-specific) and CD45 (leukocyte-specific) indicated that the majority of MPs recovered from stored pRBC units using our isolation protocol were erythrocytederived (Fig 1) . These data are consistent with previously published results from our laboratory using similar methods. 13 We next quantified viscoelastic coagulation parameters utilizing ROTEM, which is frequently utilized to identify hypercoagulability in the clinical setting. [26] [27] [28] NATEM was used to analyze the ex vivo interaction between MPs and whole blood. Compared with whole blood samples treated with a similar volume of PBS as a dilutional control, exposure of fresh whole blood to RBC-derived MPs did not significantly alter clotting time (CT; 148.7 ± 16.5 vs 212.5 ± 28.2 seconds, P = .06; Fig 2A) or mean clot formation (MCF; 65.6 ± 1.0 vs 65.0 ± 1.5 mm, P = .72; Fig 2B) . CFT (51.7 ± 7.1 vs 73.2 ± 6.7 sec; Fig 2C) and α angle (80.0 ± 1.2 degrees vs 75.5 ± 1.1 degrees; Fig 2D) , however, were affected by MP treatment compared with vehicle (each P < .05). These data suggest that MP treatment alters aspects of the clotting cascade.
To determine if microparticles isolated from stored pRBC units affected NATEM parameters in vivo, we injected mice with identical volumes of either PBS or microparticles. CT (307.2 ± 120.7 vs 334.8 ± 62.7 sec; Fig 3A) and MCF (61.0 ± 3.0 vs 57.8 ± 2.8 mm; Fig 3B) were unchanged in MP-injected mice compared with vehicle (each P = NS). Mice injected with MPs demonstrated decreased CFT (109.3 ± 26.9 vs 141.6 ± 28.2 sec; Fig 3C) and increased α angle (68.8 ± 5.0 degrees vs 62.8 ± 4.7 degrees; Fig 3D) . Taken together, these data indicate accelerated fibrinogen activation in mice treated with RBC-derived MPs (each P < .05). Both ex vivo and in vivo changes induced by MP exposure were similar among ROTEM parameters.
To determine whether thrombus composition was affected by MP transfusion, we used FIBTEM and EXTEM-derived parameters to calculate its individual components. Fibrinogen content, as estimated by the FIBTEMMCF, was not affected by RBC-derived MPs (16.6 ± 7.1 vs 15.4 ± 3.1 mm, P = NS). Platelet contribution to the clot matrix was similarly unaffected (72.6 ± 7.1% vs 73.6 ± 4.1%, P = NS, data not shown).
Based on this data, we hypothesized that RBC-derived MPs affect thrombin function, since thrombin activation (factor II) is directly responsible for conversion of fibrinogen (factor I) into fibrin (factor Ia). 29 Utilizing a thrombin generation assay ex vivo, we compared thrombin activation between RBC-derived MPs compared with saline Fig. 1 . Microparticles derived from murine pRBC units stored for 14 days yields a concentration of 10.7 ± 1.1 × 10 6 MP/ml of murine pRBCs. These microparticles are 91.08 ± 0.51% derived from erythrocyte origin, as determined by flow cytometry. Other cellular origins included platelets (0.08 ± 0.03%) and leukocytes (0.16 ± 0.60%, P < .05 each).
vehicle. Compared with controls, RBC-derived MPs produced a nearly hundredfold greater activation of thrombin substrate (66.60 ± 0.03 vs 0.70 ± 0.01 peak OD; P < .0001; Fig 4A) . Additionally, mice injected with MPs had lower circulating fibrinogen levels at 1 hour after injection, compared with PBS-injected controls (14.0 vs 16.5 μg/ mL, P < .05; Fig 4B) , further suggesting thrombin-mediated cleavage of circulating fibrinogen into insoluble fibrin strands. The presence of activated fibrin was confirmed via increased circulating D-dimer levels (1.6 ± 0.6 vs 0.9 ± 0.3 ng/mL; Fig 4C) and fibrinogen degradation product levels (1.7 ± 0.3 vs 1.3 ± 0.2 mg/mL; Fig 4D) in MP-injected mice compared with controls (P < .005 each).
To confirm the functional presence of a clinically relevant hypercoagulable state, we performed a tail bleeding assay on mice treated with saline vehicle or RBC-derived MPs (Fig 5) . Mice injected with RBC-derived MPs demonstrated a shorter interval to hemostasis at 2 hours (90.6 ± 10.8 vs 123.7 ± 5.0 sec) and 6 hours (87.1 ± 12.9 vs 141.4 ± 11.1 sec) after tail bleed, compared with PBS (each P < .05). No difference was observed at 12 or 24 hours. Furthermore, whereas PBS vehicle did not alter TBT over time (ANOVA P = NS), injection of MPs resulted in a shorter TBT that increased to match PBS controls over time (ANOVA P = .02).
Discussion
In the present study, we investigated the impact of erythrocytederived MPs from stored pRBC units on coagulation parameters of the transfusion recipient in a murine model. Both in vivo and ex vivo results identified a transient hypercoagulable state that persisted up to 6 hours after transfusion. Thrombophilic changes were detectable by ROTEM, as well as on a murine tail bleeding model. Current FDA policy allows for erythrocyte storage for up to 42 days after collection. These criteria, established in 1985, reflect the posttransfusion survival fraction and degree of hemolysis present at the end of the storage period. 11 While both measures are critical to the oxygen delivery of transfused pRBC units, together, they only account for one element of the RBC storage lesion. Other elements of the storage lesion, including metabolite depletion (e.g., ATP, glutathione), loss of membrane integrity (e.g., echinocytosis, MP vesiculation), and accumulation of immunomodulatory factors (e.g., IL-1a, MIP-1a, MIP-2) play no role in current blood banking policy. [12] [13] [14] Previous studies from our and other laboratories suggest that transfusion with stored pRBC units leads to a systemic inflammatory response, endothelial cell activation, and lung inflammation. 13, 17, 30, 31 Likewise, from a clinical standpoint, the transfusion of aged pRBCs has been associated with myriad adverse outcomes in the transfusion recipient; including deep vein thrombosis, postoperative complications, infection, multiple organ failure, and mortality. [32] [33] [34] [35] [36] [37] [38] Unfortunately, clinical studies have lacked consistency in their definition of both "fresh" and "aged" pRBCs. The definition of "fresh" most commonly refers to pRBC units <14 days old, 33, 37, 38 but this duration can range anywhere from <5 to <21 days. [39] [40] [41] [42] [43] [44] [45] Other studies have defined "fresh" through the implementation of a "freshest available" protocol, in which the youngest available pRBC unit is transfused first. [46] [47] [48] [49] Likewise, the concept of "aged" pRBC units is equally inconsistent across studies, ranging from >10 to >35 days of storage. 33, [37] [38] [39] [40] 42, 45 To provide a definitive answer to this clinical quandary, Heddle et al recently performed a large, randomized, prospective trial spanning >30,000 patients across 6 hospitals. 47 Aptly named the Informing Fresh versus Old Red Cell Management (INFORM) trial, the investigators found no differences in patient outcomes after transfusion of aged versus fresh blood. Rather than compare truly "fresh" and "aged" blood, however, the authors instead compared a "freshest available" transfusion policy to standard issue policy, where the oldest viable unit is transfused first. While each of these studies taken individually provides insight into the harms of prolonged pRBC storage, the lack of consistency across trials prevents these data from being directly comparable. Therefore, the potential harm to the recipient from stored pRBC units remains an area of ongoing research. MP formation is a key metric of prolonged pRBC storage duration, [12] [13] [14] 18 and notably, MPs also elevated in thrombogenic disease states. 50, 51 In the present study, we quantified and characterized RBC-derived MPs through common laboratory techniques. 52 Previous studies from our laboratory have demonstrated that "fresh" pRBCs contain a relatively small number of MPs, whereas the MP concentration is significantly greater in 14-day-old murine pRBCs. 13 In addition, human pRBCs have been shown to accumulate a greater concentration of MPs during storage compared with their murine counterparts, highlighting the clinical relevance of these vesicles. 13 Although the biochemical composition of these MPs has been characterized, their physiologic function remains to be fully elucidated. 18 Previous studies have described both procoagulant and anticoagulant effects of these microparticles, but their overall impact on the transfusion recipient has not been described. 20 Our data reveals that RBC-derived MPs promote hypercoagulable changes detectable through clinical measures of hemostasis. Ex vivo thromboelastometry illustrates the direct effect of MP exposure on whole blood, free of recipient-related factors (such as endothelial cell activation). 17 We validated these findings in the in vivo environment, revealing that MP-associated hypercoagulability persists within the transfusion recipient. Both ROTEM parameters and microparticle coagulant experiments suggest that activation of thrombin and accelerated cleavage of fibrinogen may be one mechanism underlying the thrombophilic phenotype. Additionally, fibrinogen levels are lower with concurrent elevation of fibrin split products in mice transfused with MPs, indicative of consumption within the recipient.
The accelerated hemostasis in the tail wound model and procoagulant properties of the microparticles may support a potential role for RBC-derived MPs in supporting hemostasis. The clinical implications of these findings, however, are less clear. While the MPs accumulated within these units may promote improved hemostasis in actively hemorrhaging patients, transfusion of older pRBC units also may contribute to posttraumatic thromboembolic events. In addition, previous research from our laboratory has demonstrated that RBC-derived MPs potentiate a number of adverse effects within the transfusion recipient. These effects include proinflammatory changes, lung injury, and activation of leukocytes and endothelial cells. 13, 17, 30, 31 With these potentially detrimental effects of RBC-derived MPs noted, any conceivable benefits of accelerated hemostasis may be outweighed by the potential ensuing harms to the acutely hemorrhaging patient.
The mechanisms of hemostasis are exceedingly complex, but can be generally categorized into 3 steps: (1) vasoconstriction, (2) platelet activation and aggregation, and (3) fibrin stabilization of the platelet plug. 29 Whereas the biochemical reactions underlying fibrinogen activation are accelerated by exposure to RBC-derived MPs, our data suggest that neither fibrinogen content nor platelet contribution to the final thrombus are affected. Thus, MPs may play an independent role in the acceleration of thrombogenesis, rather than displacing other components within the thrombus itself.
Our exclusive use of a murine model provides several strengths to our study. Donor variability in the RBC storage lesion, including MP formation, is a well-documented phenomenon in humans and would potentially limit interpretation of the ex vivo data. 53 In addition, human blood coagulation varies with diet, genetics, and a host of other factors; all of which would be difficult to control. [54] [55] [56] Through the use of genetically similar mice, we were able to remove these potentially confounding factors. Furthermore, the use of a murine model for investigating the RBC storage lesion has been established in multiple investigations from our and other laboratories. 13, 21 These findings must be interpreted with consideration for associated limitations. Our data demonstrates that MP transfusion resulted in decreased fibrinogen and elevated D-dimer in vivo. We have interpreted this finding as supporting data that MPs from aged pRBC units contribute to a hypercoagulable state. An alternative explanation for this data is that fibrinolysis is enhanced in vivo, but our ROTEM data indicates that murine blood does not undergo fibrinolysis as determined by the lysis index after 30 minutes on ROTEM (data not shown). In addition, during the in vivo experiments, we studied the effect of MPs from stored pRBC units compared with mice treated with vehicle. Data from previous studies suggest that RBCs may exert a procoagulant effect. 57, 58 In the present study, our goal was to understand the potential contribution of the MP component of stored pRBC units to clotting status, as harm from MPs could potentially be mitigated in the clinical setting. Future studies will focus on the effect of adding MPs to pRBCs.
In summary, red blood cell-derived microparticles lead to a transient hypercoagulable state in the transfusion recipient through the accelerated activation of clotting factors. Removing these potentially injurious components from aged, stored red blood cells may mitigate the development of transfusion-associated thromboembolic events.
